$PSNL News
Last published 1w ago
- 1w agoPSNLPersonalis, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoPSNLBRBSPAGAre PAG, BRBS, PSNL Obtaining Fair Deals for their Shareholders?PR NewswireInsiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
- 2w agoBWMNCCCPSNLPAGAre BWMN, PAG, CCC, PSNL Obtaining Fair Deals for their Shareholders?PR NewswireInsiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
- 2w agoDSGRPSNLVRNSAre VRNS, DSGR, PSNL Obtaining Fair Deals for their Shareholders?PR NewswireInsiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
- 3w agoPSNLPersonalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026Business WireLate-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer Personalis, Inc.
- 3w agoPSNLPersonalis Brings Resistance Mutation Tracking to NeXT Personal® MRD TestBusiness WireReal-Time Variant Tracker™ supplemental results track resistance and therapeutically targetable variants as cancer biology evolves. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today
- 3mo agoPSNLPersonalis Reports Second Quarter Results and Recent HighlightsBusiness WireClinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million Secured Medicare
- 3mo agoPSNLPSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AIGlobeNewswireMONSEY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Personalis, Inc. (NASDAQ:PSNL) ("Personalis") to Tempus AI,
- 3mo agoTEMPSNLTempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology PlatformBusiness WireAcquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across
- 4mo agoPSNLPersonalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great BritainBusiness WireRegulatory milestone for the NeXT Personal® Dx test enables clinical use of Personalis’ ultrasensitive MRD detection in Great BritainPersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology,
- 5mo agoPSNLPersonalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection KitsBusiness WireRegulatory milestone for specimen collection kits enables global deployment of Personalis' ultrasensitive MRD detection (Next Personal®) for drug development programs Personalis, Inc. (NASDAQ:PSNL), a leader in
- 5mo agoPSNLPersonalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026Business WireNeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery Ultrasensitive NeXT Personal performance was demonstrated across 6
- 5mo agoPSNLPersonalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx ConsortiumBusiness WireAbstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that six
- 5mo agoPSNLPersonalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment MonitoringBusiness WireExpanded coverage enables Medicare beneficiaries with Stage II-III TNBC or HER2+ breast cancer to access ultrasensitive MRD testing to monitor response to neoadjuvant therapy Personalis, Inc. (NASDAQ:PSNL), a leader
- 6mo agoPSNLPersonalis to Participate in Upcoming Investor EventsBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: Craig Hallum 23rd Annual
- 6mo agoPSNLPersonalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid TumorsBusiness WireExpanded coverage, supported by published data from the Vall d'Hebron Institute of Oncology (VHIO), enables Medicare beneficiaries receiving immunotherapy to access ultrasensitive MRD testing to monitor treatment
- 6mo agoPSNLPersonalis First Quarter 2026 Earnings Conference CallPERSONALIS INCEarnings Call TranscriptsGreetings and welcome to the Personale's first quarter 2026 earnings conference call. At this time all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If a
- 6mo agoPSNLPersonalis Reports First Quarter Results and Recent HighlightsBusiness WireClinical test volume surged 258% year-over-year and 26% sequentially to 7,815 tests in Q1 Medicare coverage secured for lung cancer surveillance, providing a clear path to monetize rapidly growing clinical test
- 6mo agoPSNLPersonalis to Announce First Quarter 2026 Financial ResultsBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the
- 6mo agoPSNLPersonalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026Business WirePodium presentation on NeXT Personal® monitoring neoadjuvant therapy in colorectal cancer; Real-world data from 10,000 patients reinforce industry-leading sensitivity; Data presented for a new NeXT Personal
- 7mo agoPSNLPersonalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026Business WireOral podium presentation to highlight NeXT Personal® in colorectal cancer; Personalis to debut first data for Real-Time Variant Tracker™ to monitor therapy resistance during NeXT Personal MRD
- 7mo agoPSNLPersonalis to Participate in the 25th Annual Needham Virtual ConferenceBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15,
- 7mo agoPSNLPersonalis Appoints Dr. Richard Chen as President to Further Accelerate MRD AdoptionBusiness WireDr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of
- 8mo agoPSNLPersonalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®Business WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The Pathologic
- 8mo agoPSNLPersonalis Fourth Quarter 2025 Earnings ConferencePERSONALIS INCEarnings Call TranscriptsGreetings and welcome to the Personnelis 4th Quarter 2025 Earnings Conference. At this time, all participants are in their listen-only mode. A brief question and answer session will follow the formal presentation. If any
- 8mo agoPSNLPersonalis Reports Fourth Quarter and Full Year 2025 Results and Recent HighlightsBusiness WireClinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD
- 8mo agoPSNLPersonalis to Participate in the TD Cowen 46th Annual Healthcare ConferenceBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026
- 9mo agoPSNLPersonalis to Announce Fourth Quarter and Full Year 2025 Financial ResultsBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In
- 9mo agoPSNLPersonalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer SurveillanceBusiness WireLung cancer coverage, supported by data from the landmark TRACERx collaboration, follows recent approval in breast cancer, providing access to Medicare patients. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced
- 9mo agoPSNLPersonalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid TumorsBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highlighting the power of its ultrasensitive molecular
- 9mo agoPSNLPersonalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science &
- 10mo agoPSNLPersonalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™Business WireNew NeXT Personal® extension empowers clinicians to identify emerging resistance and therapeutically targetable mutations during disease monitoring and surveillance Personalis, Inc. (NASDAQ:PSNL), a leader in
- 10mo agoONCYEXASVCYTHOLX+1Smart Oncology: 5 Stocks Chasing the $317B PrizePR NewswireThe precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in...
- 10mo agoPSNLPersonalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid TumorsBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association for Cancer Research
- 11mo agoPSNLNew Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung CancerBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study,
- 11mo agoPSNLPersonalis to Participate in the Piper Sandler 37th Annual Healthcare ConferenceBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December
- 1y agoPSNLPersonalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast CancerBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for surveillance of cancer recurrence in breast
- 1y agoPSNLPersonalis Reports Third Quarter 2025 Financial ResultsBusiness WireCompany Advances "Win-in-MRD" Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal® Platform Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for
- 1y agoPSNLPersonalis to Announce Third Quarter 2025 Financial ResultsBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the
- 1y agoPSNLPersonalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD TestingBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate that Personalis'
- 1y agoPSNLPersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on September 15, 2025, a non-qualified stock
- 1y agoPSNLCATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal TestBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced its collaboration with a leading breast cancer team from Yale Cancer Center for a clinical trial titled "A single arm
- 1y agoPSNLPersonalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD TestingBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings demonstrate that Personalis'
- 1y agoPSNLPersonalis to Participate in Upcoming Investor ConferencesBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the following conferences: Morgan Stanley 23rd Annual Global Healthcare
- 1y agoPSNLPersonalis, Inc. (PSNL) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPSNLPersonalis Reports Second Quarter 2025 Financial ResultsBusiness WireStrong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended
- 1y agoPSNLPersonalis to Announce Second Quarter 2025 Financial ResultsBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release,
- 1y agoTVGNMSFTPSNLTEMFrom Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in MedicinePR NewswireEquity Insider News Commentary – Increased usage of AI in healthcare is predicted to not only save lives, but money too. However, the rollout of this ...
- 1y agoPSNLTEMPersonalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer PatientsBusiness WireCollaboration extension through 2029 accelerates access to MRD technology across four major cancer types Personalis, Inc. (NASDAQ:PSNL) today announced an expansion and extension of its strategic collaboration with
- 1y agoPSNLPersonalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOBusiness WirePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal